SEC Form 4	
------------	--

 \Box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Γ

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					0.00	cilon 30(n)	01 11		ootimoint	00	pany no									
1. Name and Address of Reporting Person [*] Donegan Michael C					2. Issuer Name and Ticker or Trading Symbol <u>TherapeuticsMD, Inc.</u> [TXMD]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
						-									Director			10% Ov		
											X	below)	give title		Other (s below)	pecify				
(Last)	3. Date of Earliest Transaction (Month/Day/Year) 03/23/2022									CAO and VP of Finance										
951 YAMATO ROAD					03/23/2022									Gr		1 01 1	manee			
SUITE 220																				
					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)														- I '	Line)					
· /	ATON I	7L	33431											X			•	ting Person		
															Form filed by More than One Reporting					
(City)	(State)	(Zip)		Person															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1 Title of	1. Title of Security (Instr. 3) 2. Trans						action 2A. Deemed 3. 4. Securities Acquired (A) of					(A) or	or 5. Amount o		6. Ow	nership	7. Nature of			
Date (Month/E					Execution Date if any (Month/Day/Ye		e,				sed Of (D) (Instr. 3, 4			Securities Beneficial Owned Fo	lv	Form:	Direct Indirect str. 4)	ndirect Beneficial Dwnership		
									Code \	/	Amount	t (A) or (D)		Price	Reported Transactic (Instr. 3 ar				Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversior or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Cod	nsaction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exp	ate Exerc iration D nth/Day/Y	ate) Securiti Derivati		. Title and Amount o ecurities Underlying erivative Security Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivativ Securitie Beneficia Owned Followin Reported Transact	re es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	e V	(A)	(A) (D)		e rcisable	Expiration Date		Title	N	mount or umber of nares		(Instr. 4)				
Restricted Stock Units	\$0.00	03/23/2022		A		120,000			(1)		(1)	Commo Stock		20,000 ⁽¹⁾	\$0.00	120,0	00	D		

Explanation of Responses:

1. Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025.

Remarks:

<u>/s/ Michael D. Donegan</u>

** Signature of Reporting Person

03/28/2022

** Signature of Reporting Perso

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.